Gossamer Bio Inc(GOSS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -55.67 | Insider Own | 8.34% | Shs Outstand | 6.1M | Perf Week | 1.98% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 32.65% | Insider Trans | - | Shs Float | 5.6M | Perf Month | -15.19% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -3.79 | Inst Own | 72.6% | Short Float | 25.65% | Perf Quarter | -40.92% |
| Income | -0.13B | P/S | 1.12 | EPS this Y | 73.96% | Inst Trans | 36.7% | Short Ratio | 3.86 | Perf Half Y | -64.59% |
| Sales | 0.05B | P/B | - | EPS next 5Y | 45.71% | ROA | -78.81% | Short Interest | 1.44M | Perf YTD | -96.06% |
| Book/sh | -15.39 | P/C | 1.05 | EPS past 3/5Y | 34.98% 26.82% | ROE | - | 52W High | -96.84% ($309.60) | Perf Year | -94.89% |
| Cash/sh | 9.33 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 17.85% ($8.29) | Perf 3Y | -75.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.41% | Gross Margin | 98.25% | Volatility(W/M) | 8.84% 8.63% | Perf 5Y | -99.01% |
| Dividend TTM | - | EV/Sales | 0.8 | Sales Y/Y TTM | 32.43% | Oper. Margin | -297.67% | ATR (14) | 0.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.53 | EPS Q/Q | 54.54% | Profit Margin | -235% | RSI (14) | 46.7 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.53 | Sales Q/Q | -19.59% | SMA20 | -0.14% ($9.78) | Beta | 2.28 | Target Price | $95.4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -13.99% ($11.36) | Rel Volume | 0.37 | Prev Close | $9.15 |
| Employees | 162 | LT Debt/Eq | - | EPS/Sales Surpr. | 35.19% 154.57% | SMA200 | -77.85% ($44.11) | Avg Volume(3M) | 0.37M | Price | $9.77 |
| IPO | 2019/2/8 | Option/Short | No/Yes | Trades | 1774 | Volume | 138,130 | Change | 6.78% |
🫁 This is a US biopharmaceutical company that focuses on pulmonary arterial hypertension as its core disease area and is developing an inhaled therapeutic candidate called seralutinib. Based in California, the company initially maintained a broad pipeline spanning oncology and inflammation but has since narrowed its strategy to concentrate resources on a single lead asset. As a clinical-stage company, partnerships and the management of development funding form the core of its business rather than product sales.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
GOSS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $112. Peers typically go for $1,034.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #397 of 594 in the industry
Based on market cap of $60M.
FAQ
What kind of company is GOSS?
GOSS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GOSS?
The market cap of GOSS is approximately $60M, ranking 4,747 within its sector.
What is the 52-week high and low for GOSS?
GOSS has recorded a 52-week high of $309.60 and a low of $8.29.
